{
    "info": {
        "nct_id": "NCT04925934",
        "official_title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus",
        "inclusion_criteria": "* Age ≥ 18 years to ≤ 70 years\n* Willing and able to understand and provide written informed consent.\n* Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE\n* Disease duration of at least 6 months\n* Active SLE as indicated by presence of all the following:\n\n  1. SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic brain syndrome.\n  2. SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome at Screening and Baseline (Day 1).\n  3. At least one of the following BILAG 2004 Index levels of disease at Screening:\n* BILAG A disease in ≥ 1 organ system\n* BILAG B disease in ≥ 2 organ systems d. PGA score ≥ 1 on a 0 to 3 visual analog scale (VAS) at Screening\n\nHave at least one of the following at Screening per central lab:\n\n* ANA ≥ 1:80\n* Anti-dsDNA antibodies elevated to above normal range as established by the central laboratory (ie, positive results)\n* Anti-Smith antibodies elevated to above normal (ie, positive results) Ongoing treatment for SLE\n\n  1. Treatment with one or more disease-modifying anti-rheumatic drug (DMARD) or immunosuppressive medication: Any of the following medications each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight), and at a stable dose (including route of administration) for a minimum of 8 weeks prior to Screening and maintained through Baseline (Day 1):\n  2. Treatment with OGC monotherapy (without the concomitant use of DMARDs or immunosuppressants):\n\n     * Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone equivalent) for a minimum of 4 weeks prior to Screening and a stable dose for minimum of 2 weeks prior to Screening. The dose of OGC must be kept for a minimum of 2 weeks prior to Randomization. Daily dosing or alternate day dosing of PO prednisone or equivalent is allowed.\n* Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at Randomization.\n* Non-sterilized male participants who are sexually active with a woman partner of childbearing potential must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
        "exclusion_criteria": "* Any condition that, in the opinion of the Investigator, or the Sponsor/Central Review Committee, would interfere with the evaluation of the IP or interpretation of participant safety or study results (including borderline disease activity)\n* History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or a previous mAb or human Ig therapy\n* Active LN or active severe or unstable neuropsychiatric SLE\n* Current diagnosis of non-SLE vasculitis syndrome, mixed connective tissue disease, or rheumatic (overlap) syndrome\n* Participation in another clinical study with an investigational drug within 4 weeks before Day 1\n* Breastfeeding or pregnant women or women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP\n* Major surgery within 8 weeks prior to Screening or elective surgery planned from Screening through Day 393.\n* Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks before Screening\n* Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection\n* Hepatitis B, Hepatitis C, active TB, any severe herpes infection, clinically active infection, or opportunistic infection\n* History of clinically significant cardiac disease including unstable angina; and/or myocardial infarction and/or congestive heart failure within 6 months prior to Randomization.\n* History of cancer within the past 5 years except, in situ carcinoma of the cervix, cutaneous basal cell or squamous cell carcinoma with curative therapy.\n* Receipt of a live-attenuated vaccine within 4 weeks before Day 1 Administration of inactivated (killed) vaccines is acceptable\n* The use of immunosuppressants, biologics and DMARDS within the protocol defined washout periods",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Anti-dsDNA antibodies elevated to above normal range as established by the central laboratory (ie, positive results)",
                "criterions": [
                    {
                        "exact_snippets": "Anti-dsDNA antibodies elevated to above normal range as established by the central laboratory (ie, positive results)",
                        "criterion": "Anti-dsDNA antibodies",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "above normal range (as established by the central laboratory)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Anti-dsDNA antibodies elevated to above normal range as established by the central laboratory (ie, positive results)",
                        "criterion": "Anti-dsDNA antibodies",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "above normal range (as established by the central laboratory)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active SLE as indicated by presence of all the following:",
                "criterions": [
                    {
                        "exact_snippets": "Active SLE as indicated by presence of all the following",
                        "criterion": "systemic lupus erythematosus (SLE)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active SLE as indicated by presence of all the following",
                        "criterion": "systemic lupus erythematosus (SLE)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Disease duration of at least 6 months",
                "criterions": [
                    {
                        "exact_snippets": "Disease duration of at least 6 months",
                        "criterion": "disease duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Disease duration of at least 6 months",
                        "criterion": "disease duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. At least one of the following BILAG 2004 Index levels of disease at Screening:",
                "criterions": [
                    {
                        "exact_snippets": "At least one of the following BILAG 2004 Index levels of disease at Screening",
                        "criterion": "BILAG 2004 Index level of disease at Screening",
                        "requirement": {
                            "requirement_type": "presence of at least one qualifying level",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "At least one of the following BILAG 2004 Index levels of disease at Screening",
                        "criterion": "BILAG 2004 Index level of disease at Screening",
                        "requirement": {
                            "requirement_type": "presence of at least one qualifying level",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at Randomization.",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential",
                        "criterion": "sex and reproductive potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential",
                        "criterion": "sex and reproductive potential",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have a negative serum pregnancy test at screening",
                        "criterion": "serum pregnancy test at screening",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "a negative urine pregnancy test at Randomization",
                        "criterion": "urine pregnancy test at Randomization",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Women of childbearing potential",
                                "criterion": "sex and reproductive potential",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "Women of childbearing potential",
                                "criterion": "sex and reproductive potential",
                                "requirement": {
                                    "requirement_type": "childbearing potential",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "must have a negative serum pregnancy test at screening",
                        "criterion": "serum pregnancy test at screening",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "a negative urine pregnancy test at Randomization",
                        "criterion": "urine pregnancy test at Randomization",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Have at least one of the following at Screening per central lab:",
                "criterions": [
                    {
                        "exact_snippets": "Have at least one of the following at Screening per central lab",
                        "criterion": "laboratory finding (per central lab at Screening)",
                        "requirement": {
                            "requirement_type": "presence of at least one specified finding",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Have at least one of the following at Screening per central lab",
                        "criterion": "laboratory finding (per central lab at Screening)",
                        "requirement": {
                            "requirement_type": "presence of at least one specified finding",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE",
                "criterions": [
                    {
                        "exact_snippets": "Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE",
                        "criterion": "2019 EULAR/ACR Classification Criteria for SLE",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE",
                        "criterion": "2019 EULAR/ACR Classification Criteria for SLE",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Anti-Smith antibodies elevated to above normal (ie, positive results) Ongoing treatment for SLE",
                "criterions": [
                    {
                        "exact_snippets": "Anti-Smith antibodies elevated to above normal (ie, positive results)",
                        "criterion": "Anti-Smith antibodies",
                        "requirement": {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "normal range"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Ongoing treatment for SLE",
                        "criterion": "treatment for SLE",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Anti-Smith antibodies elevated to above normal (ie, positive results)",
                        "criterion": "Anti-Smith antibodies",
                        "requirement": {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "normal range"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Ongoing treatment for SLE",
                        "criterion": "treatment for SLE",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Treatment with OGC monotherapy (without the concomitant use of DMARDs or immunosuppressants):",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with OGC monotherapy",
                        "criterion": "OGC monotherapy treatment",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without the concomitant use of DMARDs or immunosuppressants",
                        "criterion": "concomitant use of DMARDs or immunosuppressants",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Treatment with OGC monotherapy",
                        "criterion": "OGC monotherapy treatment",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without the concomitant use of DMARDs or immunosuppressants",
                        "criterion": "concomitant use of DMARDs or immunosuppressants",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have maximum age of 70 Years",
                "criterions": [
                    {
                        "exact_snippets": "maximum age of 70 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "maximum age of 70 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Willing and able to understand and provide written informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Willing ... to ... provide written informed consent",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "able to understand and provide written informed consent",
                        "criterion": "ability to understand and provide written informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Willing ... to ... provide written informed consent",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "able to understand and provide written informed consent",
                        "criterion": "ability to understand and provide written informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Non-sterilized male participants who are sexually active with a woman partner of childbearing potential must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose.",
                "criterions": [
                    {
                        "exact_snippets": "Non-sterilized male participants",
                        "criterion": "sterilization status (male)",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a woman partner of childbearing potential",
                        "criterion": "sexual activity with woman partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a woman partner of childbearing potential",
                        "criterion": "sexual activity with woman partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose",
                        "criterion": "use of condom with spermicide",
                        "requirement": {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose",
                        "criterion": "use of condom with spermicide",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Non-sterilized male participants",
                                        "criterion": "sterilization status (male)",
                                        "requirement": {
                                            "requirement_type": "sterilization status",
                                            "expected_value": false
                                        }
                                    },
                                    {
                                        "exact_snippets": "sexually active with a woman partner of childbearing potential",
                                        "criterion": "sexual activity with woman partner of childbearing potential",
                                        "requirement": {
                                            "requirement_type": "sexual activity",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "sexually active with a woman partner of childbearing potential",
                                        "criterion": "sexual activity with woman partner of childbearing potential",
                                        "requirement": {
                                            "requirement_type": "partner childbearing potential",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose",
                                "criterion": "use of condom with spermicide",
                                "requirement": {
                                    "requirement_type": "agreement to use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "must agree to use a condom with spermicide from Randomization and until 3 months (approximately 5 half-lives) after receipt of the last dose",
                                "criterion": "use of condom with spermicide",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": "months"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* The use of immunosuppressants, biologics and DMARDS within the protocol defined washout periods",
                "criterions": [
                    {
                        "exact_snippets": "The use of immunosuppressants ... within the protocol defined washout periods",
                        "criterion": "immunosuppressant use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    },
                    {
                        "exact_snippets": "The use of ... biologics ... within the protocol defined washout periods",
                        "criterion": "biologic use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    },
                    {
                        "exact_snippets": "The use of ... DMARDS within the protocol defined washout periods",
                        "criterion": "DMARD use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "The use of immunosuppressants ... within the protocol defined washout periods",
                        "criterion": "immunosuppressant use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    },
                    {
                        "exact_snippets": "The use of ... biologics ... within the protocol defined washout periods",
                        "criterion": "biologic use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    },
                    {
                        "exact_snippets": "The use of ... DMARDS within the protocol defined washout periods",
                        "criterion": "DMARD use",
                        "requirement": {
                            "requirement_type": "timing relative to washout period",
                            "expected_value": "within protocol defined washout periods"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection",
                "criterions": [
                    {
                        "exact_snippets": "Known history of a primary immunodeficiency",
                        "criterion": "primary immunodeficiency",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known human immunodeficiency virus (HIV) infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known history of a primary immunodeficiency",
                        "criterion": "primary immunodeficiency",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known human immunodeficiency virus (HIV) infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current diagnosis of non-SLE vasculitis syndrome, mixed connective tissue disease, or rheumatic (overlap) syndrome",
                "criterions": [
                    {
                        "exact_snippets": "Current diagnosis of non-SLE vasculitis syndrome",
                        "criterion": "non-SLE vasculitis syndrome",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current diagnosis of ... mixed connective tissue disease",
                        "criterion": "mixed connective tissue disease",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current diagnosis of ... rheumatic (overlap) syndrome",
                        "criterion": "rheumatic (overlap) syndrome",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Current diagnosis of non-SLE vasculitis syndrome",
                        "criterion": "non-SLE vasculitis syndrome",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current diagnosis of ... mixed connective tissue disease",
                        "criterion": "mixed connective tissue disease",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current diagnosis of ... rheumatic (overlap) syndrome",
                        "criterion": "rheumatic (overlap) syndrome",
                        "requirement": {
                            "requirement_type": "current diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active LN or active severe or unstable neuropsychiatric SLE",
                "criterions": [
                    {
                        "exact_snippets": "Active LN",
                        "criterion": "lupus nephritis (LN)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                        "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                        "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                        "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active LN",
                        "criterion": "lupus nephritis (LN)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": "unstable"
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "active severe or unstable neuropsychiatric SLE",
                                "criterion": "neuropsychiatric systemic lupus erythematosus (SLE)",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": "unstable"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Receipt of a live-attenuated vaccine within 4 weeks before Day 1 Administration of inactivated (killed) vaccines is acceptable",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of a live-attenuated vaccine within 4 weeks before Day 1",
                        "criterion": "live-attenuated vaccine receipt",
                        "requirement": {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Administration of inactivated (killed) vaccines is acceptable",
                        "criterion": "inactivated (killed) vaccine receipt",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Receipt of a live-attenuated vaccine within 4 weeks before Day 1",
                            "criterion": "live-attenuated vaccine receipt",
                            "requirement": {
                                "requirement_type": "time since receipt",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Administration of inactivated (killed) vaccines is acceptable",
                            "criterion": "inactivated (killed) vaccine receipt",
                            "requirement": {
                                "requirement_type": "acceptability",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of clinically significant cardiac disease including unstable angina; and/or myocardial infarction and/or congestive heart failure within 6 months prior to Randomization.",
                "criterions": [
                    {
                        "exact_snippets": "History of clinically significant cardiac disease including unstable angina",
                        "criterion": "clinically significant cardiac disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction ... within 6 months prior to Randomization",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction ... within 6 months prior to Randomization",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure within 6 months prior to Randomization",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure within 6 months prior to Randomization",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History of clinically significant cardiac disease including unstable angina",
                                "criterion": "clinically significant cardiac disease",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "myocardial infarction ... within 6 months prior to Randomization",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "myocardial infarction ... within 6 months prior to Randomization",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "time since event",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "congestive heart failure within 6 months prior to Randomization",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "congestive heart failure within 6 months prior to Randomization",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "time since event",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or a previous mAb or human Ig therapy",
                "criterions": [
                    {
                        "exact_snippets": "History of allergy ... to any component of the IP",
                        "criterion": "allergy to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... hypersensitivity reaction ... to any component of the IP",
                        "criterion": "hypersensitivity reaction to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... anaphylaxis to any component of the IP",
                        "criterion": "anaphylaxis to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergy ... to a previous mAb or human Ig therapy",
                        "criterion": "allergy to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... hypersensitivity reaction ... to a previous mAb or human Ig therapy",
                        "criterion": "hypersensitivity reaction to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... anaphylaxis to a previous mAb or human Ig therapy",
                        "criterion": "anaphylaxis to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of allergy ... to any component of the IP",
                        "criterion": "allergy to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... hypersensitivity reaction ... to any component of the IP",
                        "criterion": "hypersensitivity reaction to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... anaphylaxis to any component of the IP",
                        "criterion": "anaphylaxis to any component of the investigational product (IP)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergy ... to a previous mAb or human Ig therapy",
                        "criterion": "allergy to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... hypersensitivity reaction ... to a previous mAb or human Ig therapy",
                        "criterion": "hypersensitivity reaction to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of ... anaphylaxis to a previous mAb or human Ig therapy",
                        "criterion": "anaphylaxis to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of cancer within the past 5 years except, in situ carcinoma of the cervix, cutaneous basal cell or squamous cell carcinoma with curative therapy.",
                "criterions": [
                    {
                        "exact_snippets": "History of cancer within the past 5 years",
                        "criterion": "history of cancer",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of cancer within the past 5 years",
                        "criterion": "history of cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except, in situ carcinoma of the cervix, cutaneous basal cell or squamous cell carcinoma with curative therapy",
                        "criterion": "history of in situ carcinoma of the cervix, cutaneous basal cell carcinoma, or squamous cell carcinoma with curative therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History of cancer within the past 5 years",
                                "criterion": "history of cancer",
                                "requirement": {
                                    "requirement_type": "time since diagnosis",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "History of cancer within the past 5 years",
                                "criterion": "history of cancer",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "except, in situ carcinoma of the cervix, cutaneous basal cell or squamous cell carcinoma with curative therapy",
                        "criterion": "history of in situ carcinoma of the cervix, cutaneous basal cell carcinoma, or squamous cell carcinoma with curative therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Breastfeeding or pregnant women or women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP",
                "criterions": [
                    {
                        "exact_snippets": "Breastfeeding ... women",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "pregnant women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP",
                        "criterion": "intention to become pregnant",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "from signing the ICF through 6 months after receiving the last dose of IP"
                        }
                    },
                    {
                        "exact_snippets": "women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP",
                        "criterion": "intention to become pregnant",
                        "requirement": {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Breastfeeding ... women",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "pregnant women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP",
                                "criterion": "intention to become pregnant",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "from signing the ICF through 6 months after receiving the last dose of IP"
                                }
                            },
                            {
                                "exact_snippets": "women who intend to become pregnant anytime from signing the ICF through 6 months after receiving the last dose of IP",
                                "criterion": "intention to become pregnant",
                                "requirement": {
                                    "requirement_type": "intention",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participation in another clinical study with an investigational drug within 4 weeks before Day 1",
                "criterions": [
                    {
                        "exact_snippets": "Participation in another clinical study with an investigational drug within 4 weeks before Day 1",
                        "criterion": "participation in another clinical study with an investigational drug",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Day 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participation in another clinical study with an investigational drug within 4 weeks before Day 1",
                        "criterion": "participation in another clinical study with an investigational drug",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Day 1"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Age ≥ 18 years to ≤ 70 years",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years to ≤ 70 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 70,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age \u001e 18 years to \u001e 70 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 70,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* BILAG B disease in ≥ 2 organ systems d. PGA score ≥ 1 on a 0 to 3 visual analog scale (VAS) at Screening",
                "criterions": [
                    {
                        "exact_snippets": "BILAG B disease in ≥ 2 organ systems",
                        "criterion": "BILAG B disease",
                        "requirement": {
                            "requirement_type": "number of organ systems involved",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "organ systems"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PGA score ≥ 1 on a 0 to 3 visual analog scale (VAS) at Screening",
                        "criterion": "PGA score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "VAS (0-3)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "BILAG B disease in \u0003 2 organ systems",
                        "criterion": "BILAG B disease",
                        "requirement": {
                            "requirement_type": "number of organ systems involved",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "organ systems"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PGA score \u0003 1 on a 0 to 3 visual analog scale (VAS) at Screening",
                        "criterion": "PGA score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "VAS (0-3)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome at Screening and Baseline (Day 1).",
                "criterions": [
                    {
                        "exact_snippets": "SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome at Screening and Baseline (Day 1)",
                        "criterion": "SLEDAI-2K total score (excluding urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome at Screening and Baseline (Day 1)",
                        "criterion": "SLEDAI-2K total score (excluding urine or laboratory results, immunologic measures, fever, SLE headache, or organic brain syndrome)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "Screening",
                                "Baseline (Day 1)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* ANA ≥ 1:80",
                "criterions": [
                    {
                        "exact_snippets": "ANA ≥ 1:80",
                        "criterion": "antinuclear antibody (ANA) titer",
                        "requirement": {
                            "requirement_type": "titer",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ":80"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ANA  1:80",
                        "criterion": "antinuclear antibody (ANA) titer",
                        "requirement": {
                            "requirement_type": "titer",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ":80"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* BILAG A disease in ≥ 1 organ system",
                "criterions": [
                    {
                        "exact_snippets": "BILAG A disease in ≥ 1 organ system",
                        "criterion": "BILAG A disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "BILAG A disease in ≥ 1 organ system",
                        "criterion": "BILAG A disease",
                        "requirement": {
                            "requirement_type": "number of organ systems involved",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "organ system"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "BILAG A disease in \u001e 1 organ system",
                        "criterion": "BILAG A disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "BILAG A disease in \u001e 1 organ system",
                        "criterion": "BILAG A disease",
                        "requirement": {
                            "requirement_type": "number of organ systems involved",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "organ system"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic brain syndrome.",
                "criterions": [
                    {
                        "exact_snippets": "SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic brain syndrome.",
                        "criterion": "SLEDAI-2K total score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic brain syndrome.",
                        "criterion": "SLEDAI-2K total score",
                        "requirement": {
                            "requirement_type": "component exclusion",
                            "expected_value": [
                                "fever",
                                "SLE headache",
                                "organic brain syndrome"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Treatment with one or more disease-modifying anti-rheumatic drug (DMARD) or immunosuppressive medication: Any of the following medications each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight), and at a stable dose (including route of administration) for a minimum of 8 weeks prior to Screening and maintained through Baseline (Day 1):",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with one or more disease-modifying anti-rheumatic drug (DMARD) or immunosuppressive medication",
                        "criterion": "treatment with DMARD or immunosuppressive medication",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight)",
                        "criterion": "DMARD or immunosuppressive medication administration",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "conventional anti-rheumatic doses"
                        }
                    },
                    {
                        "exact_snippets": "each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight)",
                        "criterion": "DMARD or immunosuppressive medication administration",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "treatment of SLE"
                        }
                    },
                    {
                        "exact_snippets": "each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight)",
                        "criterion": "DMARD or immunosuppressive medication administration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "each administered at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks before Screening (unless discontinued or dose adjusted for documented drug-related toxicity or size/weight)",
                        "criterion": "DMARD or immunosuppressive medication administration",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "discontinued for documented drug-related toxicity or size/weight",
                                "dose adjusted for documented drug-related toxicity or size/weight"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "at a stable dose (including route of administration) for a minimum of 8 weeks prior to Screening and maintained through Baseline (Day 1)",
                        "criterion": "DMARD or immunosuppressive medication dose stability",
                        "requirement": {
                            "requirement_type": "dose stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at a stable dose (including route of administration) for a minimum of 8 weeks prior to Screening and maintained through Baseline (Day 1)",
                        "criterion": "DMARD or immunosuppressive medication dose stability",
                        "requirement": {
                            "requirement_type": "route stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at a stable dose (including route of administration) for a minimum of 8 weeks prior to Screening and maintained through Baseline (Day 1)",
                        "criterion": "DMARD or immunosuppressive medication dose stability",
                        "requirement": {
                            "requirement_type": "maintenance through Baseline",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone equivalent) for a minimum of 4 weeks prior to Screening and a stable dose for minimum of 2 weeks prior to Screening. The dose of OGC must be kept for a minimum of 2 weeks prior to Randomization. Daily dosing or alternate day dosing of PO prednisone or equivalent is allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone equivalent) for a minimum of 4 weeks prior to Screening",
                        "criterion": "average daily dose of PO prednisone (or prednisone equivalent)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "mg"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 40,
                                        "unit": "mg"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone equivalent) for a minimum of 4 weeks prior to Screening",
                        "criterion": "average daily dose of PO prednisone (or prednisone equivalent)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone equivalent) for a minimum of 4 weeks prior to Screening",
                        "criterion": "average daily dose of PO prednisone (or prednisone equivalent)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "a stable dose for minimum of 2 weeks prior to Screening",
                        "criterion": "dose stability of PO prednisone (or prednisone equivalent)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a stable dose for minimum of 2 weeks prior to Screening",
                        "criterion": "dose stability of PO prednisone (or prednisone equivalent)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "The dose of OGC must be kept for a minimum of 2 weeks prior to Randomization",
                        "criterion": "dose stability of OGC",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "The dose of OGC must be kept for a minimum of 2 weeks prior to Randomization",
                        "criterion": "dose stability of OGC",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Randomization"
                        }
                    },
                    {
                        "exact_snippets": "Daily dosing or alternate day dosing of PO prednisone or equivalent is allowed",
                        "criterion": "dosing schedule of PO prednisone or equivalent",
                        "requirement": {
                            "requirement_type": "schedule",
                            "expected_value": [
                                "daily dosing",
                                "alternate day dosing"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Any condition that, in the opinion of the Investigator, or the Sponsor/Central Review Committee, would interfere with the evaluation of the IP or interpretation of participant safety or study results (including borderline disease activity)",
                "criterions": [
                    {
                        "exact_snippets": "Any condition that, in the opinion of the Investigator, or the Sponsor/Central Review Committee, would interfere with the evaluation of the IP or interpretation of participant safety or study results (including borderline disease activity)",
                        "criterion": "any condition interfering with study evaluation or interpretation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any condition that, in the opinion of the Investigator, or the Sponsor/Central Review Committee, would interfere with the evaluation of the IP or interpretation of participant safety or study results (including borderline disease activity)",
                        "criterion": "any condition interfering with study evaluation or interpretation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hepatitis B, Hepatitis C, active TB, any severe herpes infection, clinically active infection, or opportunistic infection",
                "criterions": [
                    {
                        "exact_snippets": "Hepatitis B",
                        "criterion": "Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis C",
                        "criterion": "Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "active TB",
                        "criterion": "active tuberculosis infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "any severe herpes infection",
                        "criterion": "severe herpes infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "clinically active infection",
                        "criterion": "clinically active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "opportunistic infection",
                        "criterion": "opportunistic infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hepatitis B",
                        "criterion": "Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis C",
                        "criterion": "Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active TB",
                        "criterion": "active tuberculosis infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any severe herpes infection",
                        "criterion": "severe herpes infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically active infection",
                        "criterion": "clinically active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "opportunistic infection",
                        "criterion": "opportunistic infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery within 8 weeks prior to Screening or elective surgery planned from Screening through Day 393.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "elective surgery planned from Screening through Day 393",
                        "criterion": "elective surgery",
                        "requirement": {
                            "requirement_type": "planned during study period",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "elective surgery planned from Screening through Day 393",
                        "criterion": "elective surgery",
                        "requirement": {
                            "requirement_type": "planned during study period",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks before Screening",
                "criterions": [
                    {
                        "exact_snippets": "Spontaneous or induced abortion ... ≤ 4 weeks before Screening",
                        "criterion": "abortion (spontaneous or induced)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "still or live birth ... ≤ 4 weeks before Screening",
                        "criterion": "birth (still or live)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pregnancy ≤ 4 weeks before Screening",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Spontaneous or induced abortion ... \u00104 weeks before Screening",
                        "criterion": "abortion (spontaneous or induced)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "still or live birth ... \u00104 weeks before Screening",
                        "criterion": "birth (still or live)",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pregnancy \u00104 weeks before Screening",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Screening"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}